Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting the epidermal growth factor receptor.

B F El-Rayes1, P M LoRusso

  • 1Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University 48201, USA.

British Journal of Cancer
|July 9, 2004
PubMed
Summary

Epidermal growth factor receptor (EGFR) inhibitors, including tyrosine kinase inhibitors and monoclonal antibodies, show promise in treating epithelial tumors. Clinical trials are exploring their efficacy and optimal use in various cancers, with early results indicating improved outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours.

British journal of cancer·2017
Same author

BET inhibitors: a novel epigenetic approach.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Analysis of liver-directed therapies in U.S. cancer patients.

Current oncology (Toronto, Ont.)·2015
Same author

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.

Oncogene·2013

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) is a key target in epithelial tumors, driving proliferation, metastasis, and angiogenesis.
  • EGFR inhibitors represent a significant advancement in targeted cancer therapy.
  • Two primary classes of EGFR inhibitors are under investigation: receptor tyrosine kinase (RTK) inhibitors and monoclonal antibodies.

Purpose of the Study:

  • To review the clinical development and challenges of EGFR inhibitors in cancer treatment.
  • To summarize the efficacy and safety of EGFR inhibitors in various tumor types.
  • To discuss future directions in EGFR inhibitor research and application.

Main Methods:

  • Review of clinical trial data for EGFR inhibitors.

Related Experiment Videos

  • Analysis of therapeutic strategies involving RTK inhibitors and monoclonal antibodies.
  • Evaluation of treatment outcomes in non-small-cell lung cancer, colorectal cancer, and head and neck cancer.

    • Main Results:

    • EGFR inhibitors (e.g., gefitinib) demonstrate activity in non-small-cell lung cancer after chemotherapy failure.
    • Combination therapy with monoclonal antibodies (e.g., cetuximab) and chemotherapy shows increased response rates and progression-free survival.
    • Both RTK inhibitors and monoclonal antibodies can be safely administered at effective doses.

    Conclusions:

    • EGFR inhibitors are a valuable therapeutic option for epithelial malignancies.
    • Future research should focus on identifying predictive biomarkers, combination therapies, and earlier-stage applications.
    • Optimizing clinical trial design is crucial for the successful development of EGFR inhibitors.